Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-29

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this retrospective observational study is to investigate any possible association among tacrolimus (TAC) blood concentrations, clinical efficacy and tolerability.

Therefore, the main questions it aims to answer are:

1. to clarify which variables, how and to what extent influence daily TAC blood concentrations in pediatric allo-hematopoietic stem cell transplantation (HSCT) recipients;
2. to investigate the incidence of graft-versus-host disease (GVHD) and graft failure according to TAC exposure.

Pediatric patients administered TAC to prevent GVHD after an allogeneic bone marrow transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic of Tacrolimus in Paediatric Liver Transplant Patients

NCT02337036

Liver Transplantation, Child

UNKNOWN NA

Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation

NCT02064777

Pediatric Liver Transplantation

UNKNOWN PHASE4

Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation

NCT01655563

Heart Transplantation Liver Transplantation Kidney Transplantation

COMPLETED PHASE2

Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

NCT03800576

Liver Transplantation

COMPLETED

Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients

NCT06183892

Liver Transplant

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients undergoing allo-HSCT will be recruited at IRCC Burlo Garofolo, collecting demographic and clinical characteristics from electronic medical records in a retrospective manner: age, sex, primary disease, donor type and stem cell source, body weight (BW), white blood cell (WBC) count, platelet count, red blood cell (RBC) counts, hemoglobin (HGB) and hematocrit (HCT) levels, red cell concentrate (RCC) transfusions. Other clinical laboratory data (i.e., liver and kidney function) will be included, as well as concomitant drugs administered to patients after allo-HSCT (i.e, mycophenolate mofetil, steroids, pantoprazole, voriconazole, methotrexate). Data will be collected, validated, and presented according to Good Clinical Practice (GCP) principles to support the statistical analyses and subsequent reporting. Once selected according to predefined inclusion requirements, data will be collected anonymously; an identification code will be assigned to each case. As per GCP, all collected information will be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification with user access restriction, and data will be retrievable by designated personnel only.

Because of the retrospective nature of the present research protocol, all eligible patients will be included in the study population only if their medical and laboratory records will be complete.

Statistical analyses (for descriptive and comparative aims) will be performed stratifying patients by body weight, age, gender, and source of stem cells. Univariate and multivariate tests will be used, together with Kaplan-Meyer tes, Cox proportional hazard model and ROC curve analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft Vs Host Disease Transplant Failure Stem Cell Transplant Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAC C/D ratio

Pharmacokinetics of TAC according to possible influencing factors

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tacrolimus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of the patients between 0 and 18 years (pediatric)
* Patients undergoing allogeneic bone marrow transplantation
* Patients' GVHD prophylaxis with tacrolimus
* Signed informed consent

Exclusion Criteria

* Patients undergoing autologous bone marrow transplantation
* Patients not undergoing GVHD prophylaxis
* Patients undergoing cyclosporin prophylaxis
* Incomplete pharmacokinetic/pharmacodynamic data
* Lack of any informed consent

Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No